Powder: -20°C for 3 years | In solvent: -80°C for 1 year
INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 inhibits of CN-NFAT signaling by targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 50.00 | |
10 mg | In stock | $ 86.00 | |
25 mg | In stock | $ 172.00 | |
50 mg | In stock | $ 332.00 | |
100 mg | In stock | $ 566.00 | |
500 mg | In stock | $ 1,230.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 82.00 |
Description | INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 inhibits of CN-NFAT signaling by targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site. |
In vitro | In human retinal microvascular endothelial cells, INCA-6 (1.0, 2.5 μM) significantly decreases VEGF and serum-induced proliferation without affecting baseline proliferation[1]. In 3-Hz cells, INCA-6 (5 μM) prevents transient outward K+ current downregulation[2]. INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in rat primary microglia and BV-2 cells[3]. INCA-6 (5 μM) protein expression and reduces SERCA2 transcript levels with and without thapsigargin[4]. |
In vivo | INCA-6 (2.5, 5.0, and 25.0 μM; intravitreal) significantly reduces pathologic neovascularization in oxygen-induced retinopathy and decreases the severity of OIR in a dose dependent manner[1]. |
Synonyms | Triptycene-1,4-quinone |
Molecular Weight | 284.31 |
Formula | C20H12O2 |
CAS No. | 3519-82-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.84 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
INCA-6 3519-82-2 Others factors inhibit NFAT microvascular Triptycene-1,4-quinone transcription endothelial Inhibitor retinopathy oxygen-induced retinal neovascularization INCA6 INCA 6 inhibitor